Background
Phase III, open-label RCT. 991 patients with HER2+ locally advanced or metastatic breast cancer previously treated with trastuzumab and taxane. T-DM1 (trastuzumab emtansine) was the first ADC approved in breast cancer, delivering the cytotoxic maytansinoid DM1 directly to HER2-expressing cells.
Interventions and follow up
Arm A: T-DM1 (trastuzumab emtansine) 3.6mg/kg IV q21d
Arm B: Lapatinib 1250mg oral daily + capecitabine 1000mg/m² BID days 1–14 of 21-day cycle
Primary endpoint: PFS and OS (co-primary)
mFollow up: 19.1 months (OS analysis)
Arm B: Lapatinib 1250mg oral daily + capecitabine 1000mg/m² BID days 1–14 of 21-day cycle
Primary endpoint: PFS and OS (co-primary)
mFollow up: 19.1 months (OS analysis)
Results
PFS: 9.6 vs 6.4mo, HR 0.65, 95% CI 0.55–0.77, P<.001
OS: 30.9 vs 25.1mo, HR 0.68, 95% CI 0.55–0.85, P<.001
ORR: 43.6% vs 30.8%
OS: 30.9 vs 25.1mo, HR 0.68, 95% CI 0.55–0.85, P<.001
ORR: 43.6% vs 30.8%
Adverse events
Hematologic: Grade ≥3 thrombocytopenia 14.3% vs 0.4%
Hepatic: Grade ≥3 elevated AST 4.3% vs 0.5%
Gastrointestinal: Grade ≥3 diarrhea 1.6% vs 20.7% (far lower with T-DM1)
Neurologic: Grade ≥3 peripheral neuropathy 2.2% vs 0.2%
Cardiac: LVEF decline ≥10% 2.5% vs 3.3%
Hepatic: Grade ≥3 elevated AST 4.3% vs 0.5%
Gastrointestinal: Grade ≥3 diarrhea 1.6% vs 20.7% (far lower with T-DM1)
Neurologic: Grade ≥3 peripheral neuropathy 2.2% vs 0.2%
Cardiac: LVEF decline ≥10% 2.5% vs 3.3%
Conclusions
T-DM1 significantly improved both PFS and OS compared to lapatinib + capecitabine in HER2+ mBC after trastuzumab and taxane, while demonstrating a superior tolerability profile. EMILIA provided the landmark evidence leading to the first-in-class ADC approval in breast cancer.
Key Limitations
Key Limitations: Comparator arm (lapatinib + capecitabine) is suboptimal by current standards — trastuzumab-based second-line options are preferred in current practice. This limits direct applicability to modern treatment algorithms where T-DM1 is compared to T-DXd (DESTINY-Breast03), not lapatinib combinations. Thrombocytopenia and hepatotoxicity with T-DM1 require careful monitoring. OS benefit of ~5.8 months, while significant, is modest compared to T-DXd benefits demonstrated in later trials.
Clinical Context
EMILIA established T-DM1 as second-line standard in HER2+ mBC (FDA approved 2013). For over a decade it was the benchmark second-line HER2+ treatment. DESTINY-Breast03 (2022) demonstrated T-DXd's superiority over T-DM1 with dramatically improved PFS (28.8 vs 6.8 months), effectively replacing T-DM1 as the preferred second-line option. T-DM1 now serves primarily in the adjuvant residual-disease setting, though it is also being superseded there by T-DXd (DESTINY-Breast05). ESMO-MCBS score: 5 (at time of approval).
References
References: Verma S et al, NEJM 2012